CTLA4 and neoplasm: In contrast to the lack of efficacy of the ICIs in combination with RT alone, RT in the context of fulvestrant permitted both anti-PD-L1 and anti-CTLA-4 to further slow tumor growth, confirming that the RT+Fulv treatment regimen remediated mechanisms that suppress the response to immune checkpoint blockade.